{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:08:40Z","timestamp":1792494520084,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012401","name":"Beijing Science and Technology Planning Project","doi-asserted-by":"publisher","award":["20240484711"],"award-info":[{"award-number":["20240484711"]}],"id":[{"id":"10.13039\/501100012401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005891","name":"State Administration of Traditional Chinese Medicine of the People's Republic of China","doi-asserted-by":"publisher","award":["ZYYCXTD-D-202005"],"award-info":[{"award-number":["ZYYCXTD-D-202005"]}],"id":[{"id":"10.13039\/501100005891","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Phytomedicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.phymed.2026.158272","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:02:55Z","timestamp":1777932175000},"page":"158272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Ginsenoside Rg3 improves atezolizumab immune checkpoint therapy in triple-negative breast cancer by targeting FUT8-mediated PD-L1 N-glycosylation"],"prefix":"10.1016","volume":"156","author":[{"given":"Meng","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuyun","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongjun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanting","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiqiong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6474-9198","authenticated-orcid":false,"given":"Cheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3840-5292","authenticated-orcid":false,"given":"Yuanyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phymed.2026.158272_bib0001","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3390\/ijms22010455","article-title":"FUT8 alpha-(1,6)-fucosyltransferase in cancer","volume":"22","author":"Bastian","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phymed.2026.158272_bib0002","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1158\/1078-0432.CCR-20-3407","article-title":"FDA approval summary: atezolizumab plus Bevacizumab for the treatment of patients with advanced unresectable or metastatic hepatocellular carcinoma","volume":"27","author":"Casak","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phymed.2026.158272_bib0003","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms controlling PD-L1 expression in cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phymed.2026.158272_bib0004","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1073\/pnas.1220425110","article-title":"Fucosyltransferase 8 as a functional regulator of nonsmall cell lung cancer","volume":"110","author":"Chen","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.phymed.2026.158272_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.phymed.2026.158272_bib0006","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ccell.2024.09.010","article-title":"The hallmarks of cancer immune evasion","volume":"42","author":"Galassi","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phymed.2026.158272_bib0007","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/s41419-020-03140-2","article-title":"PD-L1 degradation pathway and immunotherapy for cancer","volume":"11","author":"Gou","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.phymed.2026.158272_bib0008","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s10555-021-09972-4","article-title":"Checkpoint inhibitor therapy for metastatic triple-negative breast cancer","volume":"40","author":"Heeke","year":"2021","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.phymed.2026.158272_bib0009","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1\u2013Selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phymed.2026.158272_bib0010","doi-asserted-by":"crossref","first-page":"6349","DOI":"10.1158\/0008-5472.CAN-18-1892","article-title":"Posttranslational modifications of PD-L1 and their applications in cancer therapy","volume":"78","author":"Hsu","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.phymed.2026.158272_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2025.168040","article-title":"Liver-targeting exosomes loaded naringenin ameliorate metabolic dysfunction-associated steatotic liver disease through ubiquitin-proteasome system initiated lipophagy","volume":"523","author":"Hua","year":"2025","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.phymed.2026.158272_bib0012","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1038\/s41467-021-22618-x","article-title":"FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer","volume":"12","author":"Huang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phymed.2026.158272_bib0013","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1158\/1078-0432.CCR-16-1417","article-title":"Atezolizumab: a PD-L1\u2013blocking antibody for bladder cancer","volume":"23","author":"Inman","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phymed.2026.158272_bib0014","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.biopha.2017.09.129","article-title":"Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune","volume":"96","author":"Jiang","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.phymed.2026.158272_bib0015","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1158\/2326-6066.CIR-23-0902","article-title":"Cannabidiol enhances atezolizumab efficacy by upregulating PD-L1 expression via the cGAS\u2013STING pathway in triple-negative breast cancer cells","volume":"12","author":"Kim","year":"2024","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.phymed.2026.158272_bib0016","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1002\/cncr.31272","article-title":"Checkpoint inhibitors in triple-negative breast cancer (TNBC): where to go from here","volume":"124","author":"Kwa","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.phymed.2026.158272_bib0017","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ccell.2018.01.009","article-title":"Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1","volume":"33","author":"Li","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phymed.2026.158272_bib0018","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12951-025-03327-9","article-title":"Recombinant high-density lipoprotein targeted delivery of celastrol to promote foam cells lipophagy against early atherosclerosis","volume":"23","author":"Li","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.phymed.2026.158272_bib0019","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.phymed.2026.158272_bib0020","doi-asserted-by":"crossref","first-page":"6290","DOI":"10.1097\/JS9.0000000000002669","article-title":"Advances in cancer research on FUT8 molecular mechanisms and clinical applications","volume":"111","author":"Ma","year":"2025","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.phymed.2026.158272_bib0021","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/abt\/tbad004","article-title":"Beyond antibody fucosylation: \u03b1-(1,6)-fucosyltransferase (Fut8) as a potential new therapeutic target for cancer immunotherapy","volume":"6","author":"Mao","year":"2023","journal-title":"Antibody Ther."},{"key":"10.1016\/j.phymed.2026.158272_bib0022","first-page":"2069","article-title":"Antitumor activity of ginsenoside Rg3 in melanoma through downregulation of the ERK and akt pathways","volume":"54","author":"Meng","year":"2019","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.phymed.2026.158272_bib0023","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.phymed.2026.158272_bib0024","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1126\/science.275.5307.1787","article-title":"Activation of beta-catenin-tcf signaling in colon cancer by mutations in beta-catenin or APC","volume":"275","author":"Morin","year":"1997","journal-title":"Sci. (N.Y.)"},{"key":"10.1016\/j.phymed.2026.158272_bib0025","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1038\/s41467-024-47069-y","article-title":"Targeting branched N-glycans and fucosylation sensitizes ovarian tumors to immune checkpoint blockade","volume":"15","author":"Nie","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phymed.2026.158272_bib0026","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.celrep.2017.07.027","article-title":"Blockage of core fucosylation reduces cell-surface expression of PD-1 and promotes anti-tumor immune responses of T cells","volume":"20","author":"Okada","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.phymed.2026.158272_bib0027","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/2417418","article-title":"Ginsenoside Rg3 (Shenyi capsule) combined with chemotherapy for digestive system cancer in China: a meta-analysis and systematic review","volume":"2019","author":"Pan","year":"2019","journal-title":"Evid. Based Complement. Altern. Med. Ecam"},{"key":"10.1016\/j.phymed.2026.158272_bib0028","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1126\/science.287.5458.1606","article-title":"Wnt signaling in oncogenesis and embryogenesis\u2013a look outside the nucleus","volume":"287","author":"Peifer","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.phymed.2026.158272_bib0029","series-title":"FDA Approves Atezolizumab for PD-L1 Positive Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer","author":"Research","year":"2024"},{"key":"10.1016\/j.phymed.2026.158272_bib0030","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.chom.2013.07.012","article-title":"Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin\/\u03b2-catenin signaling via its FadA adhesin","volume":"14","author":"Rubinstein","year":"2013","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.phymed.2026.158272_bib0031","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phymed.2026.158272_bib0032","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/0008-5472.CAN-19-3133","article-title":"Targeting glycosylated PD-1 induces potent antitumor immunity","volume":"80","author":"Sun","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.phymed.2026.158272_bib0033","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3892\/ijmm.2017.2857","article-title":"Anticancer effects of ginsenoside Rg3 (review)","volume":"39","author":"Sun","year":"2017","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.phymed.2026.158272_bib0034","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12964-025-02216-w","article-title":"Glycosylation as an intricate post-translational modification process takes part in glycoproteins related immunity","volume":"23","author":"Tian","year":"2025","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.phymed.2026.158272_bib0035","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12943-022-01705-7","article-title":"lncRNA ZNRD1-AS1 promotes malignant lung cell proliferation, migration, and angiogenesis via the miR-942\/TNS1 axis and is positively regulated by the m6A reader YTHDC2","volume":"21","author":"Wang","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.phymed.2026.158272_bib0036","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2147\/JIR.S396484","article-title":"Fucosyltransferases regulated by fusobacterium nucleatum and act as novel biomarkers in colon adenocarcinoma","volume":"16","author":"Wang","year":"2023","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.phymed.2026.158272_bib0037","article-title":"Ginsenoside Rg3 targets glycosylation of PD-L1 to enhance anti-tumor immunity in non-small cell lung cancer","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phymed.2026.158272_bib0038","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12929-020-00670-x","article-title":"The impact of PD-L1\u2009N-linked glycosylation on cancer therapy and clinical diagnosis","volume":"27","author":"Wang","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.phymed.2026.158272_bib0039","doi-asserted-by":"crossref","DOI":"10.1172\/JCI186648","article-title":"Asparagine drives immune evasion in bladder cancer via RIG-I stability and type I IFN signaling","volume":"135","author":"Wei","year":"2025","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phymed.2026.158272_bib0040","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.phymed.2026.158272_bib0041","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s43556-022-00071-6","article-title":"Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy","volume":"3","author":"Yang","year":"2022","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.phymed.2026.158272_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107799","article-title":"Pharmacological mechanisms and drug delivery systems of ginsenoside Rg3: a comprehensive review","volume":"216","author":"Yao","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phymed.2026.158272_bib0043","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.phymed.2026.158272_bib0044","article-title":"Reinforced immunotherapy of M1 macrophage-derived exosomes with CEL on TNBC via regulating macrophage functions","author":"Yu","year":"2025","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.phymed.2026.158272_bib0045","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13046-021-01987-7","article-title":"Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer","volume":"40","author":"Zhang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."}],"container-title":["Phytomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711326005064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711326005064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T15:14:15Z","timestamp":1783091655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0944711326005064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":45,"alternative-id":["S0944711326005064"],"URL":"https:\/\/doi.org\/10.1016\/j.phymed.2026.158272","relation":{},"ISSN":["0944-7113"],"issn-type":[{"value":"0944-7113","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ginsenoside Rg3 improves atezolizumab immune checkpoint therapy in triple-negative breast cancer by targeting FUT8-mediated PD-L1 N-glycosylation","name":"articletitle","label":"Article Title"},{"value":"Phytomedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phymed.2026.158272","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"158272"}}